SELLAS Life Sciences Group
Manufacturing · New York, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
7 Times Sq Ste 2503, New York City, New ...Phone Number
(646) 200-5278Website
www.sellaslifesciences.comRevenue
<$5 MillionStock Symbol
SLSIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
4
1
1
1
1
1
About SELLAS Life Sciences Group
SELLAS Life Sciences Group is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies and therapeutics for a broad range of cancer indications. The Company's lead product candidate, galinpepimut-S, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a broad spectrum of hematologic cancers and solid tumor indications. SELLAS is headquartered in New York, NY.Explore more
SELLAS Life Sciences Group Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SELLAS Life Sciences Group your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if SELLAS Life Sciences Group is spiking on competitors!
SELLAS Life Sciences Group, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if SELLAS Life Sciences Group has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once SELLAS Life Sciences Group has new funding data
Earning: See what the market has to say on SELLAS Life Sciences Group recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at SELLAS Life Sciences Group
Click to see if SELLAS Life Sciences Group had a recent Job posting/layoffs
Product Launch: Get notified when SELLAS Life Sciences Group launches new products
Website visits: Recent activity has been detected on your website
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to SELLAS Life Sciences Group
Compare insights from companies similar to SELLAS Life Sciences Group, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
SELLAS Life Sciences Grou...
<$5M
11-50
Public
$20M
2012
DC
Dragan CicicSenior Vice President, Chief Development Officer
Company Profile Activity
Activity Insights
SELLAS Life Sciences Group is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
SELLAS Life Sciences Group is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about SELLAS Life Sciences Group.
SELLAS Life Sciences Group financials insights
Gather financial insights about SELLAS Life Sciences Group, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Share Placement
$20M
SELLAS Life Sciences Group Tech Stack
A closer look at the technologies used by SELLAS Life Sciences Group
Most Recent Scoops
Project
SELLAS Life Sciences Group has reported that 78 of the 80 required events have occurred in the Phase III REGAL trial for GPS, with the 80th event which will trigger the final unblinded analysis pending, with the delay in event accrual suggesting extended patient survival in the trial.
Medical Research, Clinical Operations
Pain Point
SELLAS Life Sciences Group is pursuing arbitration against 3D Medicines under the dispute resolution provisions of their license agreement, seeking $13 million, with the matter currently pending a final ruling by the Hong Kong International Arbitration Centre.
Lawsuits, Legal Affairs
Partnership
SELLAS Life Sciences Group has entered into an agreement with IMPACT-AML to expand the SLS009 clinical program into Europe, broadening patient enrollment globally in a capital-efficient manner.
Integration, Partnership
Project
anticipates reporting top-line data from its frontline AML Phase II trial of SLS009 by Q4 2026, with results potentially supporting an accelerated approval pathway or rapid progression into a registrational study if complete response rate targets are exceeded.
Medical Research, Pharmaceuticals, Clinical Operations
Project
Clinical Operations
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SELLAS Life Sciences Group
Sign Up For FreeTo access detailed company insights
SELLAS Life Sciences Group is a late-stage biopharmaceutical company focused on the development of novel cancer immunotherapies and therapeutics for a broad range of cancer indications. The Company's lead product candidate, galinpepimut-S, is a cancer immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center that targets a broad... Read More
